Accessibility settings

This paper is in the following e-collection/theme issue:

Innovations and Technology in Cancer Research (47) Secondary Use of Clinical Data for Research and Surveillance (494) Decision Support for Health Professionals (1646) Lung Cancer (74) Decision Support for Health Professionals (1646) Secondary Use of Clinical Data for Research and Surveillance (494) Cancer Prognosis Models and Machine Learning (83) Lung Cancer (74) Decision Support for Health Professionals (1646) Secondary Use of Clinical Data for Research and Surveillance (494) Cancer Prognosis Models and Machine Learning (83) Chemotherapy and Side Effects Management (124) Lung Cancer (74) Decision Support for Health Professionals (1646) Secondary Use of Clinical Data for Research and Surveillance (494)

Published on in Vol 12 (2026)

This is a member publication of Bibsam Consortium

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/84042, first published .
Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach

Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach

Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach

Authors of this article:

Luca Marzano1 Author Orcid Image ;   Asaf Dan2, 3 Author Orcid Image ;   Adam S Darwich1 Author Orcid Image ;   Luigi De Petris2, 3 Author Orcid Image ;   Salomon Tendler4 Author Orcid Image ;   Rolf Lewensohn2, 3 Author Orcid Image ;   Jayanth Raghothama1 Author Orcid Image ;   Sebastiaan Meijer1 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Luca Marzano   1 * , PhD ;   Asaf Dan   2, 3 * , MD ;   Adam S Darwich   1 , PhD ;   Luigi De Petris   2, 3 , MD, PhD ;   Salomon Tendler   4 , MD, PhD ;   Rolf Lewensohn   2, 3 , MD, PhD ;   Jayanth Raghothama   1 , PhD ;   Sebastiaan Meijer   1 , PhD

1 KTH Royal Institute of Technology, Stockholm, Sweden

2 Department of Oncology and Pathology, Karolisnka Institute, Stockholm, Sweden

3 Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden

4 Department of Medicine, Memorial Sloan Kettering Cancer Center, Ner York, NY, United States

*these authors contributed equally

Corresponding Author:

  • Adam S Darwich, PhD
  • KTH Royal Institute of Technology
  • Hälsovägen 11C, Huddinge
  • Stockholm 141 57
  • Sweden
  • Phone: 46 730647775
  • Email: darwich@kth.se